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Abstract 
A label-free immunosensor based on antibody-modified graphene field effect transistor (GFET) was 
presented. Antibodies targeting carcinoembryonic antigen (Anti-CEA) were immobilized to the 
graphene surface via non-covalent modification. The bifunctional molecule, 1-pyrenebutanoic acid 
succinimidyl ester, which is composed of a pyrene and a reactive succinimide ester group, interacts 
with graphene non-covalently via π-stacking. The succinimide ester group reacts with the amine group 
to initiate antibody surface immobilization, which was confirmed by X-ray Photoelectron 
Spectroscopy, Atomic Force Microscopy and Electrochemical Impedance Spectroscopy. The resulting 
anti-CEA modified GFET sufficiently monitored the reaction between CEA protein and anti-CEA in 
real-time with high specificity, which revealed selective electrical detection of CEA with a limit of 
detection (LOD) of less than 100 pg/ml. The dissociation constant between CEA protein and anti-CEA 
was estimated to be 6.35×10-11 M, indicating the high affinity and sensitivity of anti-CEA-GFET. Taken 
together, the graphene biosensors provide an effective tool for clinical application and point-of-care 
medical diagnostics.  
 
Keywords: Graphene; Non-covalent modification; CEA protein; Dissociation constant 
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1.  Introduction 
     Cancer has become one of the most threatening diseases all over the world. Cancer biomarkers 
are critical in cancer diagnosis and real-time monitoring of health status for patients (Biomarkers 
Definitions Working 2001). Multiple protein biomarkers are widely distributed in serum, tissues and 
saliva, and are effective indicators of disease state. In many cases, the detection of these abnormal 
markers at early stages of disease allows for rapid initiation of appropriate treatments, thereby largely 
increasing the overall chances of survival for cancer patients. As such, detection of cancer biomarkers 
is critical in diagnosis, prognosis, and prediction of treatment efficacy and recurrence of cancer 
(Giljohann and Mirkin 2009). 
Traditional biomarker detection methods include enzyme linked immunosorbent assay (Voller et al. 
1978), radioimmunoassay (Goldsmith 1975), multiplex protein assay (Kingsmore 2006), lateral flow 
immunoassay (Posthuma-Trumpie et al. 2009), fluorescent microarray and electrochemical methods 
(Chikkaveeraiah et al. 2012; Zajac et al. 2007). In these methods, expensive reagents and complex 
processes of data acquisition and quantification are required to achieve high sensitive detection. More 
importantly, most of the reactions cannot be monitored quantitatively in real-time. So a simple, 
inexpensive and highly specific detection method would allow for the assessment of target molecules 
in real-time, which would have broad clinical applications. 
Graphene is a single-atom-thick, sp2-hybridized carbon-based material. Due to its planar geometry and 
good electrical property (Geim and Novoselov 2007; Novoselov et al. 2004), graphene is an ideal 
candidate for biochemical sensors. The electrical detection of various molecules using graphene and 
graphene-like materials has been used in a number of reported devices (Schedin et al. 2007). Graphene 
field-effect transistors (GFETs) have been developed to detect DNA hybridization (Xu et al. 2014), 
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glucose (Huang et al. 2010), absorbed proteins and immunoglobulin E (Ohno et al. 2010; Ohno et al. 
2009). 
Modification of the basal plane of graphene offers a way to control its structure and electronic 
properties. Covalent binding approaches disrupt the electronic structure of graphene and take place 
preferentially at carbon atoms near defects and grain boundaries (Sun et al. 2010). Non-covalent 
functionalization strategies offer the possibility of binding functional groups to graphene without 
disturbing the electronic network (Chen et al. 2001; Georgakilas et al. 2012; Kodali et al. 2011). Pyrene 
derivatives have been found to interact non-covalently with graphene via Π-stacking (Parviz et al. 
2012). Among these derivatives, 1-pyrenebutanoic acid succinimidyl ester (PYR-NHS) contains 
aromatic pyrenyl group to interact with graphene non-covalently and succinimidyl ester group to bind 
amino probes, which can be used as a non-covalent linker to immobilize proteins such as glucose 
oxidase and glutamic dehydrogenase (Huang et al. 2010) as well as aptamers on carbon nanotube or 
graphene surfaces (Chen et al. 2001; Kodali et al. 2011; Ohno et al. 2010). 
Two important factors are considered in the use of GFETs as biochemical sensors. The first one is 
Debye screening length, which is defined as the typical distance, required for screening the charge of 
target molecules and macromolecules by the dissolved counter ions in a solution. For aqueous solutions 
at room temperature, Debye screening length depends on the ionic strength and mobile charges on the 
channel surface of GFET (Stern et al. 2007). The interaction between the capture probes and target 
molecules must occur within one Debye length. Therefore, the size of capture probes must correlate 
with the ionic strength of the accompanying buffer solution. Another consideration is the modification 
of the specificity of the capture probes without disrupting the single layer of graphene in order to 
optimize the electric properties of graphene. 
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Here, this study demonstrates a label-free antibody-modified graphene immunosensor based on non-
covalent modification. The target protein is carcinoembryonic antigen (CEA), which can be used to 
assess prognosis and monitor the progress of cancer (Casey and Kofinas 2008; Haggarty et al. 1986). 
The aromatic pyrenyl group of PYR-NHS interacts strongly with the plane of graphite via Π-stacking 
(Jaegfeldt et al. 1983; Katz 1994). The succinimidyl ester groups are highly reactive to nucleophilic 
substitution by primary and secondary amines that exist in abundance on the surface of the anti-
carcinoembryonic antigen (anti-CEA), resulting in the immobilization of anti-CEAs antibodies on the 
single layer graphene without disrupting its electronic network. Anti-CEA-modified GFET can detect 
CEA with high specificity and a LOD of less than 100 pg/ml. The dissociation constant between CEA 
protein and anti-CEA was estimated to be approximately 6.35×10-11 M by hill model. Taken together, 
this technology will have broad applications in the clinical detection of cancer. 
 
2.  Material and methods  
 
2.1. Materials and reagents 
Monoclonal antibody anti-carcinoembryonic antigen (anti-CEA) and carcinoembryonic antigen (CEA) 
protein were purchased from Medix Biochemica (Joensuu, Finland). Neuron specific enolase (NSE) 
was obtained from Fitzerald (Acton, USA) and Cytokerantin-19-fragment (CYFRA21-1) was 
purchased from Calbioreagents (California, USA). Polydimethylsiloxane (PDMS) were used to 
fabricate reactive chamber.1-pyrenebutanoic acid succinimidyl ester (PYR-NHS) and ethanolamine 
were obtained from Anaspec (California, USA) and Sigma-Aldrich (St. Louis, MO), respectively. 
Large-sized graphene films on Cu film were bought from 2D Carbon Tech Inc. (Changzhou, China). 
Ultra-pure water, obtained from Millipore Q purification system (Millipore, USA), was used for the 
preparation of all solutions. 
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2.2. Device fabrication 
Titanium/gold metal electrodes were fabricated by photolithography, metal deposition, and lift-off 
process on the substrate. The single layer graphene on Cu film generated by chemical vapor deposition 
was prepared for sensing material, by covering with a polymethyl methacrylate (PMMA) film and 
subsequently etching the graphene film using an ammonium persulfate aqueous solution, followed by 
a 5 min rinse in deionized water for three times and the PMMA/graphene film was then placed onto 
metal electrodes deposited on the substrate. The PMMA/graphene film on the substrate dried in air for 
30 min at room temperature and baked at 80℃for 30 min. The substrate was then immersed in acetone 
to dissolve the PMMA, leaving the graphene films still attached on the metal electrodes for subsequent 
device fabrication. The channel of GFETs was defined by photolithography, and the surrounding 
graphene was etched by plasma. Finally, the surface of the graphene channel was cleaned by annealing 
in pure Ar atmosphere at 400℃,and then the reaction chamber was anchored on the substrate using 
silicone. The reaction chamber was made of PDMS. One terminal of the miniaturized Ag/AgCl 
electrochemical reference electrode was fixed on the shelf and another terminal of electrochemical 
reference electrode was immersed in the reactive chamber as the gate. 
 
2.3. Modification of GFET 
To achieve non-covalent modification of the graphene surface, GFET was incubated in dry 
dimethylformamide (DMF) solution of 5mM PYR-NHS, which served as a linker, for 2 h at room 
temperature, followed by rinsing with DMF. In order to covalently immobilize anti-CEA on the 
graphene surface, the device was exposed to 2 mg/mL anti-CEA antibody in 10 mM phosphate buffer 
solution (pH 7.2) overnight. After immobilizing anti-CEA and rinsing with blank PBS, 100 mM 
ethanolamine was added onto the channel of the GFET for 1 h to deactivate and block the excess 
reactive groups remained on the graphene surface. Finally, the anti-CEA-modified GFETs were rinsed 
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with deionized water and used for subsequent detection of target molecules. 
 
2.4. Detection of anti-CEA-modified GFET 
Anti-CEA-modified GFET operated at a source voltage of 0 V, drain voltage of 0.1 V and top-gate 
voltage (Vgs) of -0.3 V in phosphate buffer solution (PBS) at pH 7.2. In order to increase the Debye 
screening length, 1µM PBS was chosen as the gate electrolyte. The miniaturized Ag/AgCl 
electrochemical reference electrode was chosen as the gate electrode. The concentration of CEA 
concentration was measured by the semiconductor parameter system (Keithley 4200). 
 
3.  Results and Discussion 
 
3.1. Device fabrication and modification 
GFETs were fabricated on silicon substrate with a 300 nm thick SiO2 layer. Using photolithography, 
metal deposition, and subsequent removal, titanium and gold were patterned on the substrate as source 
and drain electrodes. The single layer graphene film generated by chemical vapor deposition was 
transferred to metal electrodes. The channel of GFETs was defined by photolithography, and the 
surrounding graphene was etched by oxygen plasma under vacuum. The channel dimensions of these 
transistors were 25μm in width and 50μm in length. If no graphene layer on the Au electrodes, the 
absolute value of drain-source current was below 50 ÅA under different gate voltages shown in Fig. 
S1, and the drain voltage was 0.1V. The miniaturized Ag/AgCl electrochemical reference electrode 
was immersed in the reactive chamber as electrolyte-gate of GFETs. The optical micrograph of the 
graphene channel on the substrate is shown in Fig. 1(a), and a schematic diagram of the solution-gated 
GFET biosensor is shown in Fig. 1(b). If GFET had no extra encapsulation, the electrolyte-gated GFET 
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couldn’t be constructed and the graphene channel between drain and source worked as a resistance. 
The relationship curves between drain-source current and drain-source voltage were measured twice 
as shown in Fig. S2. 
Anti-CEA modified GFET was constructed by modifying graphene. In order to minimize the effects 
of modification on the intrinsic properties of graphene, a non-covalent method was used to immobilize 
capture probes on the graphene surface. 1-pyrenebutanoic acid succinimidyl ester (PYR-NHS) served 
as a linker to conjugate Anti-CEA so that these modified GFETs could be used for detecting target 
cancer molecules. The schematic diagram depicting the modification steps of GFET is presented in 
Fig. 1(c). The interaction between the Au electrode and PYR-NHS was analyzed to reflect the 
resistance of Au electrode and was shown in Fig. S3(a), and no obvious resistance value changes of 
Au electrode indicated that Au electrode bound with PYR-NHS rarely as shown in Fig. S3(b). 
 
Insert Fig. 1 
 
The graphene channel of GFET was identified by Raman spectroscopy. Raman spectroscopy of bare 
graphene and PYR-NHS-modified graphene is shown in Fig. 2(a), revealing the non-covalent 
modification of PYR-NHS on the graphene surface. Two peaks, namely, a G band at ∼1590 cm-1 and 
a 2D band at ∼2687 cm-1, were observed in the typical Raman spectra of bare graphene and PYR-
NHS-modified graphene as shown in Fig. 2(a). The almost unchanged position of the 2D Lorentzian 
peak at 2687 cm-1 after PYR-NHS incubation revealed that the electric network of graphene remained 
unperturbed (Kodali et al. 2011). As shown in Fig. 2(a), there are small D peaks in Raman spectroscopy 
of bare graphene and PYR-NHS modified graphene, which indicated that some defects existed in the 
graphene channel and could bring in defects scattering. The intensity ratio (I (2D)/I (G)) between 2D 
band and G band decreased from 1.36 to 0.84 when PYR-NHS bound to graphene. These results 
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indicated that Roman spectroscopy of PYR-NHS modified graphene was similar to that of bilayer 
graphene (Graf et al. 2007), which revealed that the binding of pyrenyl group, being highly aromatic 
in nature, on graphene, seemed to form bilayer graphene. All spectra are averaged from Raman 
mapping of 50 spots on graphene channel. This observation was verified by X-ray photoelectron 
spectroscopy (XPS) measurements. The C1s peaks of bare graphene and PYR-NHS-modified 
graphene are shown in Fig. 2(b). The results of XPS indicated that the C1s peak corresponding to sp2 
hybridization remained unchanged after PYR modification as shown in Fig. 2(b). The conversion of 
carbon centers from sp2 to sp3 changed the C1s peak into a wide envelope (Bekyarova et al. 2009), 
which was not observed in our studies.  
Similarly, the obvious shifts of transfer characteristic curves of GFETs were observed after the 
treatment of PYR-NHS as shown in Fig. 3(a). The evident shifts of transfer characteristic curves in 
Fig. 3(a) indicated the modification of PYR-NHS served as a doping effect on the graphene. These 
results were in accordance with the features of non-covalent modification. 
 
Insert Fig. 2 
 
3.2. Characterization of Covalent Conjugation of Antibodies 
After modifying the anti-CEA on the graphene, the transfer and output characteristic curves of anti-
CEA-modified GFET were evaluated and were shown in Fig. 3(b) and Fig. 4(a) respectively. The 
transfer and output characteristics of anti-CEA-modified GFETs in Fig. 3(b) and Fig. 4(a) indicated 
that the anti-CEA modification process did not destroy the intrinsic properties of the graphene. From 
the results in Fig. 3(b), we could conclude that the difference between two neighbouring Ids in the 
Section A (red box) is much larger than that in the Section B (blue box). So the gate voltages in section 
A were better choices in our measurement. According to the driving drain-source voltage (Vds) 
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suggested by other literatures (Huang et al. 2010; Ohno et al. 2010a), so we operated at a source voltage 
of 0V, drain voltage of 0.1V and top-gate voltage (Vgs) of -0.3V in our measurement. The mobility of 
anti-CEA-modified GFET was estimated to be 1400𝑐𝑚2 (𝑉 ∙ 𝑠)⁄  in the Supplementary Material. The 
leakage currents were measured under different top gate voltages while the drain voltage was 0 V. 
Compared with the values of the net change in drain currents, the leakage currents of anti-CEA-
modified GFET in Fig. 4(b) were below 100 nA, which could be considered negligible. 
 
Insert Fig. 3 
 
Atomic Force Microscopy (AFM) and Electrochemical Impedance Spectroscopy (EIS) were used to 
observe changes in the graphene channel before and after modification (detailed information regarding 
experimental results is shown in Supplementary Material). Upon addition of anti-CEA, the height in 
some parts of the graphene channel increased from 1 nm to about 7~10 nm, which is shown in Fig. S4. 
The graphene modified by PYR-NHS as well as the graphene modified by PYR-NHS bound to anti-
CEA demonstrated a gradual increase in interfacial charge transfer resistance of graphene as shown in 
Fig. S5. 
X-ray photoelectron spectroscopy (XPS) was also used to confirm successful conjugation of anti-CEA 
on the graphene surface via the succinimidyl ester group. The recorded nitrogen (N1s) spectra of XPS 
for bare graphene, PYR-NHS modified graphene and anti-CEA-modified graphene by PYR-NHS are 
shown in Fig. 5(a). In Fig. 5(a), strong N1s peaks were observed after immobilization of anti-CEA 
onto graphene using the linker PYR-NHS. Controls demonstrated that a much weaker N1s peak was 
observed on the surface of PYR-NHS-modified graphene, and that the nonspecific binding of anti-
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CEA on the graphene surface was negligible. Hence, XPS results confirmed that PYR-NHS interacted 
with graphene non-covalently, and that the linker PYR-NHS could be used to immobilize the anti-CEA 
antibody on the graphene surface. 
 
Insert Fig. 4 
 
3.3. Real-time Monitoring of CEA proteins 
     Real-time monitoring of CEA proteins was performed using the semiconductor parameter 
system. All protein solutions were diluted by phosphate buffer solution (PBS). First, the specific 
sensing characteristics of anti-CEA-modified GFET were assessed. Fig. 5(b) shows the time 
dependence curve of the drain-source current (Ids) after adding the same value of control PBS, 
carcinoembryonic antigen (CEA), neuron specific enolase (NSE) and cytokeratin-19-fragment 
(CYFRA21-1). As shown in the specific detection curves of anti-CEA-modified GFET in Fig. 5(b), 
when PBS, CYFRA21-1 and NSE were added to the buffer solution, the drain current (Ids) showed no 
obvious increase. While introducing the target CEA protein, a large increase in drain current caused 
by the binding of CEA was observed. To accelerate the reaction between anti-CEA and CEA protein, 
the solution was stirred for several seconds after the addition of each protein. When the proteins were 
added in the channel of GFET, the drain current first decreased and then stabilized. This phenomenon 
is mainly due to the equilibrium time of the solution system after stirring. When the target protein was 
introduced into the graphene channel, the drain current of bare GFET was slightly decreased while that 
of the anti-CEA-modified GFET dramatically increased, as shown in Fig. 5(b).  
These results demonstrate that the negatively charged CEA proteins were highly bound by the anti-
CEA-modified GFET, resulting in an increase in the drain current upon addition of CEA. Interestingly, 
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the addition of control proteins NSE and CYFRA21-1 did not induce a similar increase in drain current, 
which indicates that any potential nonspecific binding of graphene with non-target proteins is likely 
negligible. Taken together, anti-CEA-modified GFET demonstrates high specificity in detection of 
CEA proteins. 
Second, the drain-source current of anti-CEA-modified GFET was monitored at various CEA protein 
concentrations. The target CEA proteins at concentrations of 100 pg/ml, 1 ng/ml, 10 ng/ml, 50 ng/ml 
and 100 ng/ml were introduced into the channel of anti-CEA-modified GFET in Fig. 6(a) while the 
drain current was monitored in real-time. The isoelectric point of CEA protein was approximately 
4.4~4.7 (Casey and Kofinas 2008), indicating that these target molecules were negatively charged in 
PBS. The mechanism of action for anti-CEA modified GFET is that CAE proteins adsorbed on the 
surface of the graphene act as electron donors, resulting in conductance changes. For this reason, the 
drain current increased stepwise after injection of the target CEA at each concentration, which is shown 
in Fig. 6(a). The output characteristic curves of anti-CEA-modified GFET with constant drain voltages 
(0.1V) under different CEA concentrations were also shown in Fig. S6, and the drain current increased 
with the concentration of CEA proteins. The net change in drain current (∆I) plotted as a function of 
CEA concentration is shown in Fig. 6(b). The LOD of anti-CEA-modified GFETs was estimated to be 
less than 100 pg/ml, which is much smaller than the cut-off value (5ng/ml) in clinical diagnosis. As 
such, the high sensitivity of this biosensor demonstrates promising potential in clinical applications 
and point-of-care cancer diagnostics. 
 
Insert Fig. 5 
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3.4. Estimation of Dissociation Constant 
Lastly, using anti-CEA-modified GFETs, the dissociation constant (Kd) for the interaction between 
anti-CEA and CEA protein was estimated by monitoring the drain current (Ids) at different CEA protein 
concentrations. The results revealed that the drain-source currents increased with an increasing CEA 
protein concentration.  However, when the CEA concentrations increased to 100ng/ml, the drain-
source currents began to saturate gradually as shown in Fig. 6(b). The quantity of net drain-source 
current (∆I) was calculated as a function of CEA protein concentrations, as shown in Fig. 6(b). These 
data plotted to a nonlinear curve, indicating that the interaction between the CEA protein and Anti-
CEA on the Hill adsorption model previously described (Koopal et al. 1994; Ringot et al. 2007) 
∆I = ∆Imax𝐶𝑐𝑒𝑎
𝑛 /(K𝑑
𝑛 + 𝐶𝑐𝑒𝑎
𝑛 ) 
Where Kd is the dissociation constant of the interaction between CEA protein and anti-CEA antibody, 
∆Imax  is the saturated net drain-source current, 𝐶𝑐𝑒𝑎  is the protein concentration, n is Hill 
cooperativity coefficient of the binding interaction. 
 
Insert Fig. 6 
 
According to the fitted red curve shown in Fig. 6(b),∆Imax,Kd and n were estimated to be 3.535 
µA,11.442ng/ml and 0.237 respectively. The correlation coefficient (R2) was above 0.98 in this 
experimental results fitting, which would be used to determine the best-fitting isotherm to the 
experimental data. The calculated value of n is less than 1, which indicated the negative cooperativity 
in binding between the CEA and Anti-CEA. The molecular weight of CEA protein is about 180 kD 
(Haggarty et al. 1986). As such, this dissociation constant could also be converted into 6.35×10-11 M. 
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While the dissociation constant between the CEA protein and anti-CEA antibody has been investigated 
previously (Morris et al. 1975; Nap et al. 1992), and determined to vary from 4×10-12 M to 1×10-7 
M. Therefore, the value of the resulting dissociation constant determined in our study using anti-CEA-
modified GFETs was in accordance with previously reported results, indicating a high affinity between 
CEA protein and anti-CEA. Thus, the present antibody-modified GFET not only shows a high 
sensitivity to specifically detect target molecules, but also could be an effective tool to estimate 
dissociation constants for capture probes and target molecules. 
 
4.  Conclusions 
    A label-free antibody-modified graphene immunosensor based on non-covalent modification was 
developed and characterized in this study. Anti-CEA was immobilized in a single-layer graphene 
channel using a PYR-NHS linker. Raman spectroscopy, X-ray photoelectron spectroscopy, AFM and 
EIS confirmed the successful modification of the graphene channel using a PYR-NHS linker bound to 
anti-CEA antibody. The anti-CEA-modified GFET could achieve a LOD of CEA less than 100 pg/ml 
in real-time, with minimal nonspecific binding of non-target proteins. The dissociation constant (Kd) 
for the interaction between anti-CEA and CEA protein was estimated to be 6.35×10-11 M by hill model. 
These results indicated the high binding affinity of anti-CEA-modified GFET, and demonstrated the 
wide potential of this biosensor for clinical applications and point-of-care medical diagnostics. 
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Appendix A. Supplementary Material 
Electric detection of PYR-NHS and Anti-CEAs modified GFET, Atom Force Microscope (AFM) 
observation of GFET, Electrochemical Impedance Spectroscopy (EIS) Characterization of Graphene 
Modification. 
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Captions 
 
Fig. 1. (a) Optical micrograph of the graphene channel; (b) Schematic diagram of solution gated GFET 
biosensor; (c) The schematic diagram of all the modification steps for GFET. 
 
Fig. 2. (a) Raman spectra (excitation: 532 nm) of the graphene channel before and after PYR-NHS 
modification; (b) The C1s peaks of XPS spectra on the graphene surface before and after PYR-NHS 
modification.  
 
Fig. 3. (a) Transfer characteristics of GFET before and after modification with PYR-NHS; (b) Transfer 
characteristic curves of anti-CEA-modified GFET under different drain voltages 
 
Fig. 4. (a) Output characteristic curves of anti-CEA-modified GFET under different gate voltages; (b) 
The leakage drain currents of several Anti-CEA modified GFETs, the insert figure shows the details 
of curves. 
 
Fig. 5. (a) The recorded nitrogen spectra of XPS for bare graphene, PYR-NHS modified graphene and 
Anti-CEA modified graphene by PYR-NHS; (b) The time dependence curve of the drain-source 
current when adding PBS, NSE, CYFRE21-1 and CEA 
 
Fig. 6. (a) The time dependence curve of the drain-source current at various CEA concentration; (b) 
The net drain-source current at different CEA concentrations and a fitting red curve based on Hill 
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Fig. 2. (a) Raman spectra (excitation: 532 nm) of the graphene channel before and after PYR-NHS 
modification; (b) The C1s peaks of XPS spectra on the graphene surface before and after PYR-NHS 
modification. 
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Fig. 3. (a) Transfer characteristics of GFET before and after modification with PYR-NHS; (b) Transfer 
characteristic curves of anti-CEA-modified GFET under different drain voltages 
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Fig. 4. (a) Output characteristic curves of anti-CEA-modified GFET under different gate voltages; (b) 
The leakage drain currents of several Anti-CEA modified GFETs, the insert figure shows the details 
of curves. 
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Fig. 5. (a) The recorded nitrogen spectra of XPS for bare graphene, PYR-NHS modified graphene and 
Anti-CEA modified graphene by PYR-NHS; (b) The time dependence curve of the drain-source 
current when adding PBS, NSE, CYFRE21-1 and CEA 
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Fig. 6. (a) The time dependence curve of the drain-source current at various CEA concentration; (b) 
The net drain-source current at different CEA concentrations and a fitting red curve based on Hill 
adsorption model is presented. 
